<p>Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit</p>

Abstract

Background: Inaccurate diagnosis in COPD is a current problem with relevant consequences in terms of inefficient health care, which has not been thoroughly studied in primary care medicine. The aim of the present study was to evaluate the degree of inaccurate diagnosis in Primary Care in Spain and study the determinants associated with it. Methods: The Community Assessment of COPD Health Care (COACH) study is a national, observational, randomized, non-interventional, national clinical audit aimed at evaluating clinical practice for patients with COPD in primary care medicine in Spain. For the present analysis, a correct diagnosis was evaluated based on previous exposure and airway obstruction with and without the presence of symptoms. The association of patient-level and center-level variables with inaccurate diagnosis was studied using multivariate multilevel binomial logistic regression models. Results: During the study 4,307 cases from 63 centers were audited. The rate of inaccurate diagnosis was 82.4% (inter-regional range from 76.8% to 90.2%). Patient-related interventions associated with inaccurate diagnosis were related to active smoking, lung function evaluation, and specific therapeutic interventions. Center-level variables related to the availability of certain complementary tests and different aspects of the resources available were also associated with an inaccurate diagnosis. Conclusions: The prevalence data for the inaccurate diagnosis of COPD in primary care medicine in Spain establishes a point of reference in the clinical management of COPD. The descriptors of the variables associated with this inaccurate diagnosis can be used to identify cases and centers in which inaccurate diagnosis is occurring considerably, thus allowing for improvement.

Ten Research Questions for Improving COPD Care in the Next Decade

“…Finally, it also impacts on the health system leading to potential extra costs [29]. The reasons behind this high proportion or inaccurate diagnosis are multifactorial, where a low perception of symptoms among the population [30] combined with limited resources [31] and low awareness among physicians [32] combine to give rise to a perfect storm.…”

Predictors of Single Bronchodilation Treatment Response for COPD: An Observational Study with the Trace Database Cohort

“…Firstly, although the starting sample size is large, the number of patients receiving monotherapy is more limited, which results in decreased statistical power and some potential associations not reaching statistical significance. The advancement of new treatments for COPD that provide greater bronchodilator and anti-inflammatory power, as well as the combination of several drugs in a single inhalation device, has led to single therapies being used less often [ 14 , 15 , 16 , 17 ]. In reality, this attitude towards stepping-up therapy has been widely adopted, although it may not be the most suitable approach, as we point out in our work.…”

Plasma Fibrinogen as a Biomarker of Stable and Exacerbated Chronic Obstructive Pulmonary Disease

“…Globally, 10 -95% under-diagnosis and 5 -60% overdiagnosis of disease are prevalent due to the unavailability of spirometry in rural areas of the developing countries, untrained technical operators to perform the test, and their lack of skill in interpretating the results of spirometry [12,13]. The diagnosis of COPD can only be declared if patients have a combination of certain symptoms, "a post-bronchodilator fixed ratio of Forced Expiratory Volume in 1 st second and Forced Vital Capacity, i.e., FEV1/FVC < 0.7, measured by spirometry [14]. Hence in the absence of any reliable and accurate diagnostic criteria, there is a dire need to search for some authenticated markers for the diagnosis of COPD.…”